Leukemia

The information below is intended for use by health care providers only. Please consult with your health care provider for more information about clinical trials.

A041702 Ibrutinib + Obinutuzumab Vs Ibrutinib + Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70) with CLL

Study Details

  • Study Site/Tumor Location: Leukemia
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Both
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information

E1910 Blinatumomab in new DX ALL

Study Details

  • Study Site/Tumor Location: Leukemia
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Both
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information

EA9161 Addition of Venetoclax to Ibrutinib and Obinutuzumab vs Ibrutinib and Obinutuzumab in Untreated Younger Patients with CLL

Study Details

  • Study Site/Tumor Location: Leukemia
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Both
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information